

Research Ethics Committee Reference Number	Name of Trial	Target number of patients available	Target number of patients	Date Agreed to recruit target number of patients available	Date Agreed to recruit target number of patients	Trial Status	Target met within the agreed time
09/H707/60	A Principal Open-label Study to Assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects with Amnesic Mild Cognitive Impairment who will Convert to Probable Alzheimer's Disease.	Available	30	Available	31/10/2010	Closed - Follow Up Complete	N
09/H1102/67	Effect of Passive Immunization on the Progression of Alzheimer's Disease: LY2062430 versus Placebo	Available	20	Available	31/05/2011	Closed - Follow Up Complete	N
09/H0305/79	Neurobiological Correlates of Antidepressant Response After Duloxetine Hydrochloride Treatment in Subjects with Major Depressive Disorder	Available	88	Available	18/02/2011	Closed - Follow Up Complete	N
11/LO/0152	A Clinical Evaluation of Different Device Parameters for the Management of patients with Treatment Resistant Major Depressive Disorder, single or recurrent episode, with Deep Brain Stimulation	Available	8	Available	30/09/2012	Closed - In Follow Up	N
10/H7015/26	Observational Study Description F1D-MC-B034(a) Post-Injection Syndrome in Patients with Schizophrenia Receiving Olanzapine Long-Acting Injection	Available	11	No Date Agreed With Sponsor		Open	N/A
10/H604/94	Study to evaluate the efficacy and safety of RO4917838 in patients with sub-optimally controlled symptoms of schizophrenia treated	Available	6	Available	31/12/2012	Closed - Follow Up Complete	Y
10/H0606/69	Study to evaluate efficacy and safety of RO4917838 in stable patients with persistent, predominant negative symptoms of schizophrenia	Available	6	Available	30/11/2012	Closed - Follow Up Complete	Y
11/EM0093	A pilot study in treatment of iatrogenic weight gain and dyslipidaemia associated with olanzapine treatment in subjects with functional psychosis.	Available	10	Available	31/03/2012	Closed - Follow Up Complete	N
11/IE/0166	Biomarker Study: Impact of Single Doses of LY2979165 and LY2140023 on the Ketamine-Challenge Pharmacological MRI Assay in Healthy Male Subjects	Available	32	No Date Agreed With Sponsor		Closed - In Follow Up	N/A
10/H1102/85	Protocol H8A-MC-LZAO Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid 3 Antibody in Patients with Alzheimer's Disease	Available	5	No Date Agreed With Sponsor		Closed - In Follow Up	Y
11/SC/0547	An exploratory substudy to the phase III studies NN25307 NN25310 to assess the effects of RO4917838 treatment on glutamate brain levels and prefrontal activation in patients with schizophrenia.	Available	20	Available	31/12/2012	Open	N
10/H0408/88	A study of a transition to flexibly dosed paliperidone palmitate in patients with schizophrenia previously unsuccessfully treated with oral or long-acting injectable antipsychotics.	Available	5	Available	01/01/2012	Closed - Follow Up Complete	N
11/LO/1528	Study of the effects of Buprenorphine Hemihydrate Hydrochloride/Naloxone Hydrochloride Dihydrate intravenous co-administration in opiate dependant patients	Available	32	Available	31/12/2012	Closed - Follow Up Complete	N
12/NW/0296	A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of AMG 747 on Negative Symptoms in Subjects with Schizophrenia.	Available	6	Available	30/09/2013	Withdrawn	N/A
12/LO/1490	A Phase II, randomised, single-centre, open-label, two-arm study to determine the safety and efficacy of buprenorphine oral lyophilisate (Xprenor) in comparison with buprenorphine sublingual tablets (Subutex) in opioid-dependent patients	Available	36	Available	30/04/2013	Closed - Follow Up Complete	Y
12/SC/0687	A study to investigate the efficacy and safety of RO4602522 added to the background therapy of the acetylcholinesterase inhibitors donepezil or rivastigmine in patients with Alzheimer's disease	Available	6	No Date Agreed With Sponsor		Closed - Follow Up Complete	N/A
12/SC/0544	A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS) in Nonsmokers	Available	10	Available	30/09/2013	Closed - In Follow Up	N
13/LO/1183	Randomized, Double-blind, Placebo-controlled, Cross-over Study to Evaluate Functional Magnetic Resonance Imaging (fMRI) of the Brain with Administration of Risperidone, Olanzapine, Haloperidol, Alprazolam or Placebo in Healthy Subjects	Available	42	Available	31/03/2015	Open	N/A
13/LO/0702	A Randomized, Double-blind, Placebo-controlled, Parallel, 26-Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy	Available	6	Available	31/10/2014	Closed - In Follow Up	N/A
13/SC/0332	A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneously Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD48335R 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects	Available	200	Available	01/10/2018	Open	N/A
12/SC/0443	A Randomized, Double-Blind, Placebo Controlled, 3-period, Proof of Mechanism, Cross-Over Study of Roflumilast (100 or 250 µg) administered up to Steady State to Evaluate the Effects of Add-on Roflumilast to Second Generation Antipsychotics on Cognitive Impairment as well as Brain Imaging (ie, fMRI) and Electrical Activity (ie, EEG) Changes Observed in Subjects With Stable Schizophrenia	Available	15	Available	31/12/2014	Open	N/A

13/SC/0386	Long Term Safety and Efficacy of ABT126 in Subjects with Schizophrenia: A Double Blind Extension Study for Subjects Completing Study M10-855	Available	4	Available	31/07/2014	Withdrawn	N/A
13/NW/0777	A double-blind, randomised, placebo-controlled, parallel group study of GWP42003 as adjunctive therapy in the first line treatment of schizophrenia or related psychotic disorder	Available	8	Available	30/06/2015	Open	N/A
13/SC/0628	A randomized, double-blind, placebo-controlled, parallel-group proof of concept study to evaluate the effect of AFQ056 in obsessive compulsive disorder (OCD) patients resistant to Selective Serotonin Reuptake Inhibitor (SSRI) therapy	Available	2	Available	30/11/2014	Suspended	N/A
14/LO/0359	A Multicenter 26-Week Extension Study to Evaluate the Safety and Clinical Effects of Prolonged Exposure to 1 and 2mg Doses of EVP-6124, and Alpha-7 Nicotinic Acetylcholine Receptor Agonist, as an Adjunctive Pro-cognitive Treatment in Subjects with Schizophrenia on Chronic Stable Atypical Antipsychotic Therapy	Available	6	Available	31/12/2015	Open	N/A
13/SC/0120	A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Efficacy and Safety Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease	Available	4	Available	28/02/2015	Open	N
14/SS/1018	Randomised, double blind, parallel group, placebo controlled, fixed dose study of Lu AE58054 in patients with mild-moderate Alzheimer's disease treated with donepezil, study 2	Available	6	Available	17/03/2016	Open	N/A
14/LO/2127	A randomized, double-blinded, placebo and lorazepam-controlled, four-way crossover, Phase II study to evaluate the effects of single oral administration of BNC210 on brain activity changes captured by functional magnetic resonance imaging in adults with Generalized Anxiety Disorder	Available	24	Available	01/03/2017	Open	N/A